Inositol monophosphatase 2 (IMP 2) (IMPase 2) (EC 3.1.3.25) (Inositol-1(or 4)-monophosphatase 2) (Myo-inositol monophosphatase A2)
1_MKPSG 6_ EDQAA 11_ LAAGP 16_ WEECF 21_ QAAVQ 26_ LALRA 31_ GQIIR 36_ KALTE 41_ EKRVS 46_ TKTSA 51_ ADLVT 56_ ETDHL 61_ VEDLI 66_ ISELR 71_ ERFPS 76_ HRFIA 81_ EEAAA 86_ SGAKC 91_ VLTHS 96_ PTWII 101_ DPIDG 106_ TCNFV 111_ HRFPT 116_ VAVSI 121_ GFAVR 126_ QELEF 131_ GVIYH 136_ CTEER 141_ LYTGR 146_ RGRGA 151_ FCNGQ 156_ RLRVS 161_ GETDL 166_ SKALV 171_ LTEIG 176_ PKRDP 181_ ATLKL 186_ FLSNM 191_ ERLLH 196_ AKAHG 201_ VRVIG 206_ SSTLA 211_ LCHLA 216_ SGAAD 221_ AYYQF 226_ GLHCW 231_ DLAAA 236_ TVIIR 241_ EAGGI 246_ VIDTS 251_ GGPLD 256_ LMACR 261_ VVAAS 266_ TREMA 271_ MLIAQ 276_ ALQTI 281_NYGRD
1: Phosphatase that can use myo-inositol monophosphates, myo-inositol 1,4-diphosphate, scyllo-inositol-1,4-diphosphate, glucose-1-phosphate, beta-glycerophosphate and 2'-AMP as substrates in vitro (PubMed:17068342). It is likely that IMPA2 has an as yet unidentified in vivo substrate(s) (PubMed:17068342). Has been implicated as the pharmacological target for lithium (Li(+)) action in brain (PubMed:17068342)